Neurocrine Biosciences, Inc. (NBIX) Insider Dimitri E. Grigoriadis Sells 30,000 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Dimitri E. Grigoriadis sold 30,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the insider now owns 77,691 shares of the company’s stock, valued at approximately $5,794,194.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $74.64 on Tuesday. Neurocrine Biosciences, Inc. has a 1 year low of $37.35 and a 1 year high of $75.98. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period last year, the firm earned ($0.43) earnings per share. sell-side analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Neurocrine Biosciences, Inc. (NBIX) Insider Dimitri E. Grigoriadis Sells 30,000 Shares” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/11/14/neurocrine-biosciences-inc-nbix-insider-dimitri-e-grigoriadis-sells-30000-shares.html.

Several large investors have recently made changes to their positions in the company. Graticule Asia Macro Advisors LLC purchased a new stake in shares of Neurocrine Biosciences in the third quarter valued at about $2,004,000. Stifel Financial Corp purchased a new stake in shares of Neurocrine Biosciences in the third quarter valued at about $246,000. Dimensional Fund Advisors LP raised its holdings in shares of Neurocrine Biosciences by 3.2% in the third quarter. Dimensional Fund Advisors LP now owns 181,751 shares of the company’s stock valued at $11,135,000 after buying an additional 5,554 shares during the last quarter. Brown Advisory Inc. raised its holdings in shares of Neurocrine Biosciences by 10.1% in the third quarter. Brown Advisory Inc. now owns 273,272 shares of the company’s stock valued at $16,745,000 after buying an additional 25,115 shares during the last quarter. Finally, Moody Aldrich Partners LLC raised its holdings in shares of Neurocrine Biosciences by 13.2% in the third quarter. Moody Aldrich Partners LLC now owns 22,256 shares of the company’s stock valued at $1,364,000 after buying an additional 2,591 shares during the last quarter.

Several equities analysts have commented on the stock. Cowen and Company restated an “outperform” rating and issued a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Citigroup Inc. reaffirmed a “buy” rating and set a $79.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $72.00 price objective (up from $67.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 10th. Finally, Barclays PLC lifted their price objective on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $78.88.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply